A postoperative TAPSE/PASP ratio <0.52 mm/mmHg independently predicted increased long-term all-cause mortality after TAVI, with HR 0.856 per 0.1 mm/mmHg increase (P=0.033).
Observational (n=786)
No
Does a postoperative TAPSE/PASP ratio <0.52 mm/mmHg predict long-term all-cause mortality in patients undergoing transfemoral TAVI?
Effect estimate: HR 0.856 per 0.1 mm/mmHg increase in postoperative TAPSE/PASP (95% CI 95% CI 0.743-0.988)
Absolute Event Rate: 12.6% vs 5.1%
p-value: p=0.033
Lower postoperative TAPSE/PASP (<0.52 mm/mmHg) is independently associated with increased long-term mortality after TAVI, supporting its use for early postoperative risk stratification.
Uzel et al. (Thu,) conducted a observational in Adults undergoing transfemoral transcatheter aortic valve implantation (TAVI) with postoperative echocardiographic assessment (n=786). Postoperative TAPSE/PASP ratio assessment vs. Postoperative TAPSE/PASP ratio ≥0.52 mm/mmHg was evaluated on Long-term all-cause mortality (HR 0.856 per 0.1 mm/mmHg increase in postoperative TAPSE/PASP, 95% CI 95% CI 0.743-0.988, p=0.033). A postoperative TAPSE/PASP ratio <0.52 mm/mmHg independently predicted increased long-term all-cause mortality after TAVI, with HR 0.856 per 0.1 mm/mmHg increase (P=0.033).